Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ZYTIGA is substantial. |
Clinical Added Value
| moderate |
ZYTIGA provides a moderate improvement in actual benefit (level III) in terms of efficacy and tolerance in the treatment of metastatic castration-resistant prostate cancer which progresses during or after docetaxel therapy. |
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
QWASxZKDRY74YVPW
